MYX enters Scheme Implementation Deed with Gedeon Richter
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA ENTERS INTO A SCHEME IMPLEMENTATION
DEED WITH GEDEON RICHTER
Key Points:
• Acquisition price for Mayne Pharma Shares of A$6.40 per share in cash
• Scheme Consideration values Mayne Pharma’s equity at approximately A$604 million
• Consideration represents a significant 99.4% premium to the pre-announcement share price
• The Mayne Pharma Board unanimously recommends that Mayne Pharma shareholders vote in
favour of the Scheme in the absence of a Superior Proposal and subject to the Independent Expert
concluding (and continuing to conclude) that the Scheme is in the best interests of Mayne Pharma
shareholders
Mayne Pharma CEO Mr Aaron Gray and CFO Mr Griffin Buchanan will host a webcast of the transaction at
11:00am AEDT today (7:00pm US Eastern Time on 16 November 2026) – Details Below
17 November 2026, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX), (Mayne Pharma)
announces that it has entered into a Scheme Implementation Deed (SID) with Gedeon Richter Plc.
(Richter), pursuant to which Richter (through its wholly owned Australian nominee company to
be incorporated) has agreed to acquire 100% of the shares in Mayne Pharma by way of a Scheme
of Arrangement (Scheme) at a price of A$6.40 per share (Scheme Consideration), with Richter
obliged to ensure that the Scheme Consideration is paid in accordance with the terms of the SID.
Richter is a specialty pharmaceutical company, founded in Hungary 125 years ago, with
operations in around 50 countries globally. With expertise in Women’s Health, Neuropsychiatry,
Biotechnology and General Medicines, Richter’s activities range from original research and
development, through manufacturing, to trade and marketing.
Overview of the Scheme
The Scheme Consideration of A$6.40 per share values Mayne Pharma’s equity at approximately
A$604 million1
and represents a premium of:
• 99.4% to Mayne Pharma’s closing share price as at 16 November 2026;
• 124% premium to the 30-day volume weighted average price (VWAP);
• 122% premium to the 90-day VWAP; and
• 145% premium to the 180-day VWAP.
The Scheme is fully funded and subject to limited customary conditions, including certain
regulatory approvals, approval by Mayne Pharma shareholders at the Scheme meeting (with a
Scheme booklet and an independent expert’s report to be provided to Mayne Pharma
shareholders) and Court approval.
1
Based on i) approximately 94.4 million Mayne Pharma shares, taking into account Mayne Pharma’s ordinary shares on issue and
equity incentives on issue or proposed to be issued, and ii) assuming the Mayne Pharma Convertible Notes are converted into shares
when they mature on 31 December 2026.
ASX Announcement
Page 2
The Scheme is subject to an additional condition precedent that Mayne Pharma completes the
sale of its International business segment to Evaris Pharma, as announced to the ASX on 6
November 2026, which is subject to Australian Competition and Consumer Commission (ACCC)
approval but not to Foreign Investment Review Board (FIRB) approval (International Business
Divestment).
Mayne Pharma Chair, Prof Bruce Robinson, AC said “The Board has carefully considered the
proposal from Richter and has unanimously concluded that it is in the best interests of Mayne
Pharma shareholders, intheabsenceofa SuperiorProposaland subjecttotheIndependent Expert’s
conclusion. The Scheme Consideration of A$6.40 per share in cash provides shareholders with the
opportunity to realise value at a significant premium to recent trading prices and recognises the
strengthof MaynePharma’sWomen’s Healthand Dermatology/DistributeRx franchises intheUnited
States. The Board’s priority throughout has been to maximise value and certainty for all
shareholders. Together with the recent binding agreement to sell our International business to
Evaris Pharma, the Scheme delivers on that priority.”
Mr Aaron Gray, CEO of Mayne Pharma said “Today’s announcement reflects the quality of the
business ourteam has built. Wehaveestablished MaynePharma as a leaderinWomen’sHealthand
Dermatology in the United States, with expanded patient access through the DistributeRx platform
launch in March 2026. More recently with the agreed divestment of the International business to
Evaris Pharma, we are simplifying the Company around a single market focus within the United
States. The offer from Richter recognises the value of that work. Richter brings significant additional
scale and capability to support the next phase of growth for our brands, our people and the patients
weserve. On behalf of the management team, I thank ouremployees for theircommitment toMayne
Pharma. Until the Scheme is implemented it remains business as usual, and our focus is unchanged
in delivering for patients, prescribers and customers alike.”
Mr László Kovács, Deputy CEO of Richter, said “We are very excited about the opportunity this
acquisition provides for both companies and for our patients. Innovation has been at the core of
making Richteroneof theleading players inwomen’s healthinEuropeand beyond. Mayne’s existing
portfolio – including our estetrol-based innovative combination contraceptive pill – and its
commercial footprint provide a strong base to build on and will allow us to bring new treatments to
millions of women in the United States across several therapeutic segments, where there is
significant unmet medical need. We believe our offer reflects full value to Mayne shareholders, and
also creates value for Richter shareholders through accelerating expanding our footprint in the
world’s largest pharmaceutical market.”
Recommendation
The Mayne Pharma Board unanimously recommends that Mayne Pharma shareholders vote in
favour oftheScheme, in theabsence of a Superior Proposal and subject toan independent expert
concluding(and continuingtoconclude) thattheSchemeisin thebest interestsofMaynePharma
shareholders.
Subject to these qualifications, each Mayne Pharma Director has confirmed that they intend to
vote any shares that they hold or control in favour of the Scheme. In respect of non-executive
director Mr Jacob Ma-Weaver, this includes the shares held by Funicular Funds, LP (being 9.82%
of the ordinary shares of the Company). Mr Ma-Weaver is the Managing Member of Cable Car
Capital, LP, the General Partner of Funicular Funds, LP.
ASX Announcement
Page 3
Major investors
Mayne Pharma’s three largest shareholders, Funicular Funds (9.82%), Mr Bruce Mathieson (6.46%)
and Trium Capital (5.85%), who currently collectively own 22.14% of the ordinary shares of the
Company have each notified Mayne Pharma that they intend to vote all shares held by them on
the record date for the Scheme Meeting in favour of the proposed transaction in the absence of a
Superior Proposal.
The Mayne Pharma Convertible Notes issued on 31 December 2022 are scheduled to mature on
31 December 2026. The holder, Rubric Capital, is entitled to make an election to redeem or
convert its ConvertibleNotes priorto thematurity. Ifthe notesare converted,theconversion price
will be A$5.356 per share and Rubric will receive 7,685,488 ordinary Mayne Pharma shares that will
participate in the Scheme, if implemented.
Overview of the Scheme Implementation Deed (SID)
The implementation of the Scheme is subject to certain conditions precedent, including:
• Certain regulatory approvals as set out in the SID, including by the Foreign Investment
Review Board, as well as under the United States Hart-Scott-Rodino Antitrust
Improvements Act;
• Mayne Pharma shareholder approval;
• The independent expert concluding (and continuing to conclude) that the Scheme is in
the best interests of Mayne Pharma shareholders;
• Approval by the Court;
• No restraints under any order or injunction made by any court or government agency
preventing implementation of the Scheme;
• No Mayne Pharma material adverse change;
• No prescribed occurrences;
• No convertible securities (being performance rights and restricted stock units on issue in
Mayne Pharma) being on issue on the Scheme Record Date; and
• Completion of the International Business Divestment.
The Scheme is not subject to any financing condition, with Richter funding the acquisition out of
its internal cash resources.
The parties have agreed to file a voluntary declaration with the Committee on Foreign Investment
in the United States (CFIUS) in connection with the transaction. Through CFIUS, the US
Government has certain powers to restrain transactions which would cease to apply if and when
the declaration (or subsequent notice, if applicable) is approved or the waiting period otherwise
expires. If CFIUS sought to restrain the transaction, that could result in the failure of the ‘no
restraints’ condition described above. The parties are working towards, and it is anticipated that,
this voluntary process will be concluded ahead of the second court hearing as detailed in the
transaction timeline below.
The SID contains customary exclusivity obligations on Mayne Pharma, including “no-shop”, “no-
talk”, and “no due diligence” obligations (the latter two obligations being subject to a customary
ASX Announcement
Page 4
fiduciary exception), “notification” obligations, and a matching right regime that applies to any
superior proposal received by Mayne Pharma. The SID also contains customary break fee and
reverse break fee provisions.
The terms of the transaction with Richter, including conditions, deal protections, termination
rights and break fees, are agreed and set out in the SID attached to this announcement.
Indicative timetable and next steps
Mayne Pharma shareholders do not need to take any action at this stage.
A Scheme Booklet containing information relating to the Scheme, the reasons for the Directors’
recommendation, the Independent Expert’s Report opining on whether the Scheme is in the best
interests of Mayne Pharma shareholders and details of the Scheme Meeting will be dispatched to
shareholders in due course in advance of the Scheme Meeting.
Mayne Pharma shareholders will be given the opportunity to vote on the Scheme at a Scheme
Meeting, which is currently expected to be held in late January. If the Scheme is approved by
Mayne Pharma shareholders and the other conditions precedent are satisfied or waived, the
Scheme is expected to be implemented in March.
These dates are indicative, subject to change and conditional on (among other things) regulatory
approval, and shareholder approval at the Scheme Meeting.
Event Expected Date
First Court Hearing Mid December 2026
Dispatch of Scheme Booklet to Mayne Pharma Shareholders Mid-December 2026
Scheme Meeting Late January 2027
Second Court Date March 2027
Effective Date Mid to late March 2027
Implementation Date Mid to late March 2027
Advisors
Mayne Pharma is being advised by Leerink Partners as sole financial adviser and Gilbert + Tobin
and Arnold & Porter as legal advisers.
Richter is being advised by H.C. Wainwright & Co. as financial adviser and Johnson Winter Slattery
and Hogan Lovells Cadwalader as legal advisers.
Investor Webinar
Mayne Pharma’s CEO Mr Aaron Gray and CFO Mr Griffin Buchanan will host a webcast of the
transaction at 11:00am AEDT today, 17 November 2026(7:00pm US Eastern Time on 16 November
2026).
Participants can register for the webcast / teleconference by navigating to: https://s1.c-
conf.com/diamondpass/10058438-ya9sbs.html
ASX Announcement
Page 5
Click here to view this announcement on Mayne Pharma’s Investor Hub.
Follow us on LinkedIn
For further information contact:
Mayne Pharma
Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com
Media enquiries about Richter
Justine Pirie
SEC Newgate Australia
+61 435 325 954
Justine.Pirie@secnewgate.com.au
Authorised for release to the ASX by the Board of Directors.
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising
novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne
Pharma is a leader in dermatology and women’s health in the United States and also provides
contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-
year track record of innovation and success in developing new oral drug delivery systems. These
technologies have been successfully commercialised in numerous products that continue to be
marketed around theworld. Tolearn more about MaynePharma, pleasevisit maynepharma.com.
About Richter
Richter aspires to be a global innovator in some key scientific fields, while dedicated to making
medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a
market capitalization of EUR 4.8bn and sales of EUR 2.3bn in 2025, it operates Central Europe's
largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare,
while Biotechnology and General Medicines strengthen its affordable treatment portfolio.
Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and
digitalization to advance medical innovation. Learn more at www.gedeonrichter.com.
Scheme implementation deed
Mayne Pharma Group Limited
Gedeon Richter Plc.
Gilbert + Tobin page | i
Contents Page
1 Defined terms and interpretation 1
2 Agreement to proceed with Transaction 2
3 Conditions precedent 4
4 Implementation steps and Scheme Booklet 13
5 Conduct of business and transitional matters 19
6 Public Announcements 31
7 Exclusivity 31
8 Break Fee and Reverse Break Fee 36
9 Warranties 40
10 Releases 42
11 Termination 43
12 Confidentiality Deed 45
13 Guarantee and indemnity 45
14 Duty, costs and expenses 47
15 GST 47
16 General 48
Schedule 1 Dictionary 52
Schedule 2 Mayne Pharma Warranties 66
Schedule 3 Gedeon Richter Warranties 70
Schedule 4 Prescribed Occurrences 72
Schedule 5 Indicative Timetable 74
Execution page 75
Attachment A Scheme 77
Attachment B Deed Poll 78
Gilbert + Tobin page | 1
Date: 17 November 2026
Parties
1 Mayne Pharma Group Limited ACN 115 832 963 of 1538 Main North Road,
Salisbury South, South Australia 5106, Australia (Mayne Pharma)
2 Gedeon Richter Plc. of 1103 Budapest, Gyömrői út 19–21, Hungary (Gedeon
Richter)
Background
A The parties have agreed that Gedeon Richter BidCo will acquire Mayne Pharma by
means of a scheme of arrangement under Part 5.1 of the Corporations Act
between Mayne Pharma and Scheme Shareholders.
B Mayne Pharma and Gedeon Richter have agreed to implement the Scheme on and
subject to the terms of this deed.
C Gedeon Richter has agreed to guarantee the obligations of Gedeon Richter BidCo
under the Deed Poll, on and subject to the terms of this deed.
The parties agree
1 Defined terms and interpretation
1.1 Defined terms
A term or expression which is defined in the dictionary in Schedule 1 has the meaning
given to it in the dictionary.
1.2 Interpretation
The interpretation clause in Schedule 1 sets out rules of interpretation for this deed.
1.3 Reasonable endeavours
Unless expressly provided for in this deed, any provision of this deed that requires a party
to use its best endeavours, reasonable endeavours or all reasonable endeavours, or to
take all steps reasonably necessary, to ensure that something is performed or occurs, or
does not occur, does not include any obligation:
(a) to pay any money or to provide any financial compensation, valuable consideration
or any other incentive to or for the benefit of any person:
(i) in the form of an inducement or consideration to a Third Party; or
(ii) in circumstances that are commercially onerous or unreasonable in the
context of the parties’ intention to implement the Transaction on the terms of
this deed,
other than the payment of any applicable lodgement, filing or application fee to any
Government Agency or immaterial expenses or costs (including costs of advisers);
Gilbert + Tobin page | 2
(b) to commence any legal action or proceeding against any person; or
(c) for the avoidance of doubt, to procure absolutely that that thing is performed or
occurs, or does not occur.
1.4 Effect of the International Business Divestment
Other than as expressly contemplated, references in this deed to:
(a) the parties’ obligations to procure certain things of the members of the Mayne
Pharma Group;
(b) ensure the Mayne Pharma business is, or is not, operated in a particular way
(including the restrictions in clause 5) or other references to the Mayne Pharma
Group; and
(c) any representation or warranty in relation to Mayne Pharma or its business,
do not apply in relation to and will exclude the International Business.
2 Agreement to proceed with Transaction
2.1 Mayne Pharma to propose Scheme
(a) Mayne Pharma agrees to propose the Scheme on and subject to the terms of this
deed.
(b) Mayne Pharma must not consent to any modification of, or amendment to, the
Scheme, or to the making or imposition by the Court of any condition in respect of
the Scheme, without the prior written consent of Gedeon Richter (such consent not
to be unreasonably withheld or delayed).
(c) Gedeon Richter agrees to assist Mayne Pharma in proposing and implementing
the Scheme on and subject to the terms of this deed.
2.2 Scheme Consideration
(a) Each Scheme Shareholder will be entitled to receive the Scheme Consideration in
respect of each of their Scheme Shares, on and subject to the terms of the
Scheme.
(b) Subject to the Scheme becoming Effective, Gedeon Richter undertakes and
warrants to Mayne Pharma (in Mayne Pharma’s own right and separately as
trustee for each of the Scheme Shareholders) that, in consideration of the transfer
to Gedeon Richter BidCo of all Scheme Shares pursuant to the terms of the
Scheme, Gedeon Richter will procure that Gedeon Richter BidCo:
(i) accepts that transfer on the Implementation Date; and
(ii) pays, or procure the payment of, an amount equal to the Aggregate Scheme
Consideration in cleared funds into a trust account operated by Mayne
Pharma as trustee for the Scheme Shareholders before 12 noon on the
Business Day immediately before the Implementation Date.
Gilbert + Tobin page | 3
2.3 Mayne Pharma Board recommendation
(a) Mayne Pharma must use best endeavours to procure that each Mayne Pharma
Director:
(i) recommends to Mayne Pharma Shareholders that they vote in favour of the
resolution to approve the Scheme (Recommendation); and
(ii) announces their intention to cause any Mayne Pharma Shares in which they
have a Relevant Interest to be voted in favour of the resolution to approve
the Scheme (Voting Intention Statement),
in each case, qualified only by the absence of a Superior Proposal and subject to
the Independent Expert concluding, and continuing to conclude, that the Scheme is
in the best interests of Mayne Pharma Shareholders.
(b) Mayne Pharma must use best endeavours to procure that no Mayne Pharma
Director changes, withdraws or modifies their Recommendation or Voting Intention
Statement unless:
(i) pursuant to clause 7.7(a)(ii);
(ii) the Independent Expert concludes that the Scheme is not or is no longer in
the best interests of Mayne Pharma Shareholders; or
(iii) the Mayne Pharma Board determines, after receiving written legal advice
from Mayne Pharma’s external legal adviser, that the fiduciary or statutory
duties of the Mayne Pharma Directors require them to change or withdraw
their Recommendation or Voting Intention Statement (for a reason other than
a Competing Proposal).
(c) Mayne Pharma must ensure that the Scheme Booklet and all material public
announcements by Mayne Pharma in relation to the Scheme (other than
announcements as to purely administrative matters) will repeat the Mayne Pharma
Directors’ Recommendation and Voting Intention Statement.
2.4 Gedeon Richter BidCo
(a) Gedeon Richter intends to and is in the process of incorporating a new Australian
subsidiary entity that will be named ‘Gedeon Richter Australia BidCo Pty Ltd’, or
any variation or substantially similar name provided any such name is available to
be registered by ASIC (Gedeon Richter BidCo) to acquire all of the Scheme
Shares under the Scheme by giving written notice to Mayne Pharma as soon as
practicable following the date of this deed (BidCo Notification).
(b) Gedeon Richter will enter into, and will procure that Gedeon Richter BidCo enters
into, the Deed Poll and:
(i) Gedeon Richter must procure that Gedeon Richter BidCo complies with its
obligations under, and completes the acquisition in accordance with the
terms of, the Scheme and the Deed Poll;
(ii) Gedeon Richter must procure that Gedeon Richter BidCo complies with this
deed as though it were a party to it (in the position of Gedeon Richter); and
(iii) despite the foregoing:
Gilbert + Tobin page | 4
(A) Gedeon Richter will continue to be bound by all of the obligations of
Gedeon Richter under this deed and will not be released from any
obligations or liabilities under this deed following the BidCo
Notification; and
(B) Mayne Pharma will continue to owe its obligations under this deed to
Gedeon Richter (except to the extent expressly stated in this deed).
3 Conditions precedent
3.1 Conditions
Subject to this clause 3, the Scheme will not become Effective until and unless the
following Conditions are satisfied or waived in accordance with clause 3.6:
(a) FIRB approval: Before 8:00am on the Second Court Date:
(i) Gedeon Richter has received written notice under the FATA, by or on behalf
of the Treasurer of the Commonwealth of Australia (Treasurer), advising
that (or to the effect that) the Commonwealth Government of Australia has
no objections to the Transaction, either unconditionally or subject to
conditions acceptable to Gedeon Richter, acting reasonably;
(ii) following the giving of notice of the Transaction under the FATA, the
Treasurer becomes precluded by passage of time from making an order or
decision under Division 2 of Part 3 of the FATA in respect of the Transaction,
and the ten day period referred to in section 82(2)(a) of the FATA has ended
or the period referred to in section 82(2)(b) of the FATA has ended
(whichever is applicable); or
(iii) where an interim order is made under section 68 of the FATA in respect of
the Transaction, the subsequent period for making an order or decision
under Part 3 of the FATA elapses without the Treasurer making such an
order or decision,
and in the case of subparagraph (i) above, the notice of no objection has not been
withdrawn, suspended or revoked before 8.00am on the Second Court Date.
(b) HSR clearance: Before 8:00am on the Second Court Date the waiting period
under the HSR Act has been terminated or expired and any commitment to a
Government Agency to refrain from implementing the Scheme has expired, been
released, or otherwise been terminated, either conditionally or subject to conditions
acceptable to Gedeon Richter, acting reasonably.
(c) Independent Expert: The Independent Expert concludes in the Independent
Expert’s Report that the Scheme is in the best interests of Mayne Pharma
Shareholders (and does not adversely change that conclusion) before 8:00am on
the Second Court Date.
(d) Court approval: The Court approves the Scheme in accordance with section
411(4)(b) of the Corporations Act.
(e) Mayne Pharma Shareholder approval: Mayne Pharma Shareholders approve the
Scheme at the Scheme Meeting by the requisite majorities under section 411(4)(a)
of the Corporations Act.
Gilbert + Tobin page | 5
(f) No restraints: No restraining order, injunction or other order that would prevent the
Scheme, made by a court of competent jurisdiction or Government Agency on the
application of a Government Agency, is in effect as at 8:00am on the Second Court
Date.
(g) No Prescribed Occurrence: No Prescribed Occurrence occurs between the date
of this deed and 8:00am on the Second Court Date.
(h) No Material Adverse Change: No Material Adverse Change occurs, is announced
or becomes known to Gedeon Richter between the date of this deed and 8:00am
on the MAC Expiry Date.
(i) International Business Divestment: Before 8:00am on the Second Court Date,
the International Business Divestment completes in all material respects pursuant
to the International Business SPA.
(j) Mayne Pharma Convertible Securities: As at 8.00am on the Second Court Date,
Mayne Pharma has complied with its obligations under clause 4.3, including by
obtaining all relevant approvals, executing all relevant agreements and documents
and otherwise in a manner acceptable to Gedeon Richter (acting reasonably), such
that there will be no Mayne Pharma Convertible Securities on the Record Date.
3.2 Best endeavours
(a) Mayne Pharma must, to the extent within its power to do so, use best endeavours
to procure that the Conditions in clauses 3.1(g), 3.1(h) and 3.1(i) are satisfied.
(b) Each of Mayne Pharma and Gedeon Richter must, to the extent within its power to
do so, use best endeavours to procure that:
(i) the Conditions in clauses 3.1(a), 3.1(b), 3.1(c), 3.1(d), 3.1(e) and 3.1(f) are
satisfied as soon as practicable after the date of this deed; and
(ii) there is no occurrence within its control or the control of any of its Related
Bodies Corporate that would prevent any Conditions being satisfied.
(c) Mayne Pharma will not be in breach of its obligations under clause 3.2(a) or 3.2(b)
in relation to the Condition in clause 3.1(h) to the extent that it takes or omits to
take any action as permitted by clause 5.1 or 5.2(a)(v) that it reasonably believes is
in the best interests of the Ongoing Mayne Pharma Group even if doing so
adversely impacts, or may adversely impact, EBITDA in the financial years ended
30 June 2027 or 30 June 2028.
(d) In respect of the Condition in clause 3.1(h) (No Material Adverse Change), if a
Material Adverse Change becomes known to Gedeon Richter between the date of
this deed and 5.00pm on the second Business Day prior to the MAC Expiry Date,
the Condition in clause 3.1(h) (No Material Adverse Change) will not be taken to
have been breached or not satisfied, unless:
(i) a party has given written notice to the other party of the Material Adverse
Change in accordance with clause 3.8(b)(i); and
(ii) Mayne Pharma has not remedied the Material Adverse Change within seven
Business Days (or any shorter period ending at 5.00pm on the Business Day
prior to the MAC Expiry Date) after the date on which such notice is given.
Gilbert + Tobin page | 6
(e) In respect of the Condition in clause 3.1(g) (No Prescribed Occurrence), if a
Prescribed Occurrence occurs and becomes known to Gedeon Richter between
the date of this deed and 5.00pm on the second Business Day prior to the Second
Court Date, the Condition in clause 3.1(g) (No Prescribed Occurrence) will not be
taken to have been breached or not satisfied, unless:
(i) a party has given written notice to the other party of the Prescribed
Occurrence in accordance with clause 3.8(b)(i); and
(ii) Mayne Pharma has not remedied the Prescribed Occurrence within seven
Business Days (or any shorter period ending at 5.00pm on the Business Day
prior to the Second Court Date) after the date on which such notice is given.
3.3 Regulatory Approvals and communications with Government Agencies generally
(a) Gedeon Richter agrees to use its best endeavours to agree any conditions or
undertakings reasonably required or requested by or on behalf of the relevant
Government Agency on terms acceptable to Gedeon Richter (acting reasonably)
(including by way of offering such conditions or undertakings), if reasonably
necessary to obtain a Regulatory Approval. This clause 3.3(a), clause 3.2(b)(i) and
any requirement in clause 3.1 that Gedeon Richter acts reasonably in connection
with a Regulatory Approval:
(i) will, if so requested by FIRB, require Gedeon Richter to accept, in relation to
the Condition in clause 3.1(a) (FIRB approval), the Standard Tax Conditions
and customary data protection or privacy conditions imposed by FIRB
(provided that Mayne Pharma may negotiate the precise terms of them as
contemplated above); but
(ii) do not, for the avoidance of doubt, require Gedeon Richter to agree or offer
any condition or undertaking:
(A) that would require any member of the Gedeon Richter Group or
Mayne Pharma Group to sell, hold separate, divest, or discontinue,
before or after the Implementation Date, any of their assets,
businesses, or interests or shorten the exclusivity period of any
product sold by the Gedeon Richter Group or Mayne Pharma Group;
or
(B) relating to the operations of any such assets, businesses, or interests
that could reasonably be expected to materially adversely impact the
economic or business benefits to Gedeon Richter of the Transaction;
or
(C) that would require any member of the Gedeon Richter Group or
Mayne Pharma Group to make any materially adverse modification or
waiver of the terms and conditions of this deed, the Scheme, Deed
Poll or International Business Divestment Documents.
Gilbert + Tobin page | 7
(b) Without limiting clause 3.2, but subject to clause 3.3(d), each of Gedeon Richter
and Mayne Pharma must:
(i) not do, and must ensure that its Related Bodies Corporate, Representatives
and their respective directors, officers, employees, advisers, agents or
anyone acting on its behalf do not do, any of the following:
(A) apply to any Government Agency for any approval, consent,
clearance, waiver, concession or similar in connection with the
Transaction; or
(B) send or otherwise initiate any substantive submission, notification or
communication to any Government Agency or make or permit to be
made any public statement, in connection with the Transaction,
including indirectly through lobbyists or third parties (including the
media),
in each case other than:
(C) in respect of a Regulatory Approval or as otherwise expressly
contemplated by this deed, and in accordance with this clause 3 to the
extent applicable;
(D) as required by law or the rules of any securities exchange on which
the party or any of its Related Bodies Corporate are listed; or
(E) with the prior written consent of t
Share your feedback
Discover